What was the overall market valuation of the UK immunosuppressive drugs market in 2024?

The overall market valuation was $310.76 Million in 2024. Read More

What is the projected market valuation for the UK immunosuppressive drugs market by 2035?

The projected valuation for 2035 is $751.03 Million. Read More

What is the expected CAGR for the UK immunosuppressive drugs market during the forecast period 2025 - 2035?

The expected CAGR during the forecast period 2025 - 2035 is 8.35%. Read More

Which companies are considered key players in the UK immunosuppressive drugs market?

Key players include Roche, Novartis, Bristol-Myers Squibb, AbbVie, Merck & Co., Amgen, Pfizer, Astellas Pharma, and Sanofi. Read More

What were the valuations for oral and intravenous drugs in the UK immunosuppressive drugs market?

Oral drugs were valued at $124.0 Million, while intravenous drugs were valued at $150.0 Million. Read More

How do the valuations of different drug classes compare in the UK immunosuppressive drugs market?

Corticosteroids were valued at $60.0 Million, while calcineurin inhibitors reached $70.0 Million. Read More

What applications dominate the UK immunosuppressive drugs market?

Kidney transplants are projected to have a valuation of $80.0 Million, followed by organ transplants at $50.0 Million. Read More

What is the market size for hospitals and clinics as end-users in the UK immunosuppressive drugs market?

Hospitals and clinics are projected to have a market size of $180.76 Million. Read More

What is the valuation range for antiproliferative agents in the UK immunosuppressive drugs market?

Antiproliferative agents are valued between $50.0 Million and $120.0 Million. Read More

What is the expected growth trend for the UK immunosuppressive drugs market in the coming years?

The market is expected to grow significantly, reaching $751.03 Million by 2035. Read More

UK Immunosuppressive Drugs Market

ID: MRFR/Pharma/49155-HCR

200 Pages

Rahul Gotadki

Last Updated: April 06, 2026

UK Immunosuppressive Drugs Market Research Report: Size, Share, Trend Analysis By Drug Type (Calcineurin Inhibitors, Corticosteroids, Antiproliferative Agents, mTOR Inhibitors, Others), By Route of Administration (Intravenous, Oral, Others), By Applications (Autoimmune Disease, Organ Transplant, Kidney Transplant, Heart Transplant, Others) and By End Users (Hospitals and Clinics, Organ Transplant Centers, Others)- Growth Outlook & Industry Forecast 2025 To 2035

UK Immunosuppressive Drugs Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)8.35%

2024 Market Size$ 310.76 Million

2025 Market Size$ 336.71 Million

2035 Market Size$ 751.03 Million

Key Players

Roche

Novartis

Bristol-Myers Squibb

AbbVie

Merck & Co.

Amgen

Trends

Rising Demand for Targeted Therapies
Advancements in Drug Delivery Systems
Regulatory Changes and Accelerated Approvals

Opportunities

Growing Demand for Organ Transplantation
Increasing Prevalence of Autoimmune Diseases
Technological Advancements in Drug Development

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Chemicals and Materials, BY Route of Administration (USD Million)
  1. 4.1.1 Oral Drugs
  2. 4.1.2 Intravenous Drugs
  3. 4.1.3 Others
2. 4.2 Chemicals and Materials, BY Drug Class (USD Million)
  1. 4.2.1 IMDH inhibitors
  2. 4.2.2 mTOR inhibitors
  3. 4.2.3 Antiproliferative agents
  4. 4.2.4 Corticosteroids
  5. 4.2.5 Calcineurin inhibitors
  6. 4.2.6 Monoclonal antibodies
  7. 4.2.7 Others
3. 4.3 Chemicals and Materials, BY Application (USD Million)
  1. 4.3.1 Organ transplants
  2. 4.3.2 Kidney Transplants
  3. 4.3.3 Liver Transplants
  4. 4.3.4 Heart Transplants
  5. 4.3.5 Others
  6. 4.3.6 Autoimmune disease
  7. 4.3.7 Localized Autoimmune Disease
  8. 4.3.8 Systemic Autoimmune Disease
4. 4.4 Chemicals and Materials, BY End-user (USD Million)
  1. 4.4.1 Organ transplant centers
  2. 4.4.2 Hospitals and clinics
  3. 4.4.3 Others
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Chemicals and Materials
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Chemicals and Materials
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Roche (CH)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Novartis (CH)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Bristol-Myers Squibb (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 AbbVie (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Merck & Co. (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Amgen (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Pfizer (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Astellas Pharma (JP)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Sanofi (FR)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 UK MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
3. 6.3 UK MARKET ANALYSIS BY DRUG CLASS
4. 6.4 UK MARKET ANALYSIS BY APPLICATION
5. 6.5 UK MARKET ANALYSIS BY END-USER
6. 6.6 KEY BUYING CRITERIA OF CHEMICALS AND MATERIALS
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF CHEMICALS AND MATERIALS
9. 6.9 DRIVERS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
10. 6.10 RESTRAINTS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
11. 6.11 SUPPLY / VALUE CHAIN: CHEMICALS AND MATERIALS
12. 6.12 CHEMICALS AND MATERIALS, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
13. 6.13 CHEMICALS AND MATERIALS, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Million)
14. 6.14 CHEMICALS AND MATERIALS, BY DRUG CLASS, 2024 (% SHARE)
15. 6.15 CHEMICALS AND MATERIALS, BY DRUG CLASS, 2024 TO 2035 (USD Million)
16. 6.16 CHEMICALS AND MATERIALS, BY APPLICATION, 2024 (% SHARE)
17. 6.17 CHEMICALS AND MATERIALS, BY APPLICATION, 2024 TO 2035 (USD Million)
18. 6.18 CHEMICALS AND MATERIALS, BY END-USER, 2024 (% SHARE)
19. 6.19 CHEMICALS AND MATERIALS, BY END-USER, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  2. 7.2.2 BY DRUG CLASS, 2025-2035 (USD Million)
  3. 7.2.3 BY APPLICATION, 2025-2035 (USD Million)
  4. 7.2.4 BY END-USER, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

UK Chemicals and Materials Market Segmentation

Chemicals and Materials By Route of Administration (USD Million, 2025-2035)

Oral Drugs
Intravenous Drugs
Others

Chemicals and Materials By Drug Class (USD Million, 2025-2035)

IMDH inhibitors
mTOR inhibitors
Antiproliferative agents
Corticosteroids
Calcineurin inhibitors
Monoclonal antibodies
Others

Chemicals and Materials By Application (USD Million, 2025-2035)

Organ transplants
Kidney Transplants
Liver Transplants
Heart Transplants
Others
Autoimmune disease
Localized Autoimmune Disease
Systemic Autoimmune Disease

Chemicals and Materials By End-user (USD Million, 2025-2035)

Organ transplant centers
Hospitals and clinics
Others

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”